GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

Pharmadrug PHRX.CN · CAD

N/A · Canadian Securities Exchange · 🇨🇦 Canada

Compare

0.01

0.00%

Close of 5 Nov 2026, in CAD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Popular Bitcoin Ethereum Nvidia Apple S&P 500 Gold EUR/USD US 10Y

At a glance

Figures in CAD, from our data supplier.

FY2025

Revenue

—

FY2016FY2025

Net income

−C$383,377

FY2016FY2025

Free cash flow

−C$87,513

FY2016FY2025

Shareholders' equity

−C$1.8m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue————C$7,009C$683,671C$610,600———
Research and development—C$137,898C$226,352C$712,683C$553,768————C$400
Operating income−C$225,933−C$668,658−C$1.4m−C$2.5m−C$2.8m−C$3.8m−C$5.1m−C$950,500−C$114,800−C$185,900
Net income−C$383,377−C$793,267−C$13.2m−C$8.9m−C$5.9m−C$5.2m−C$6.3m−C$3.9m−C$114,800−C$7.5m
Diluted earnings per share-0.00-0.01-0.15-0.17-0.12-0.15-0.09-0.28-0.00-0.30

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsC$551,661C$711,804C$1.2mC$12.1mC$19.5mC$13.7m—C$1.1mC$100,100C$114,600
Cash and short-term investments———————C$155,100C$1,100C$12,600
Total liabilitiesC$2.2mC$2.0mC$2.7mC$3.3mC$2.7mC$2.8m—C$1.6mC$21,200C$72,000
Debt————C$786,374C$1.0m—C$1.1m——
Shareholders' equity−C$1.8m−C$1.4m−C$1.7mC$8.8mC$16.9mC$9.7m—−C$490,300C$79,000C$42,600
Shares outstanding108m108m88m51m49m35m70m14m25m25m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−C$87,513−C$756,623−C$671,881−C$2.3m−C$4.1m−C$1.8m—−C$1.3m−C$129,600−C$43,400
Capital spending—−C$11,976——−C$42,718−C$17,966−C$19,045——−C$185,600
Free cash flow−C$87,513−C$768,599−C$671,881−C$2.3m−C$4.2m−C$1.8m—−C$1.3m−C$129,600−C$229,000

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Operating income−C$31,312−C$46,985−C$115,125−C$30,853−C$30,399−C$49,556−C$100,288−C$56,488
Net income−C$243,739−C$186,740−C$133,447−C$77,182−C$72,636−C$100,111C$6,084−C$171,277
Diluted earnings per share-0.00-0.00-0.00-0.00-0.00-0.000.00-0.00
Total assetsC$752,217C$907,937C$551,661C$557,244C$578,372C$662,168C$711,804C$764,952
Shareholders' equity−C$1.8m−C$1.6m−C$1.8m−C$1.6m−C$1.6m−C$1.5m−C$1.4m−C$1.5m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income-55.1%-43.3%-10.9%
Net income-64.9%-40.5%-0.3%

Valuation history

At each fiscal year end

FY2025FY2024
Price to earnings-0.0-0.0

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 7-to-1 reverse split · 24 Oct 2023
  • 20-to-1 reverse split · 2 Aug 2016

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.